
|Videos|July 12, 2016
- Gastrointestinal Cancers: mCRC (Issue 9)
- Volume 1
- Issue 9
Overview of the Lume 1 and 2 Trials
Author(s)Axel Grothey, MD
Axel Grothey, MD, Mayo Clinic in Rochester, Minnesota, discusses the Lume 1 and 2 trials as well as new treatment options for metastatic colorectal cancer.
Advertisement
Articles in this issue
almost 10 years ago
Role of DPR in Colorectal Canceralmost 10 years ago
Impact of HER2 Amplification in Colorectal Canceralmost 10 years ago
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancyalmost 10 years ago
Novel Immunotherapy Combinations on Horizon for mCRCalmost 10 years ago
SIRT Added to First-line Chemo Improves Response in Colorectal CancerAdvertisement
Related Content
Advertisement



Pelareorep-Based Regimen Shows Durable Activity in RAS-Mutant mCRC
Published: | Updated:


Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5






























